导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 32.41% | 71/4773 |
| 近一周 | -1.96% | 966/5462 |
| 近一月 | -6.84% | 3642/5421 |
| 近一季 | -14.51% | 4164/5209 |
| 近半年 | 26.96% | 76/4920 |
| 近一年 | 42.10% | 98/4366 |
| 近两年 | 209.01% | 67/2954 |
| 近三年 | 160.70% | 28/2253 |
| 成立以来 | 191.73% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.56% 2367/4961 |
88.00% 137/5312 |
- - |
- - |
| 2025 | 65.79% 144/4813 |
3.12% 1184/3635 |
2.92% 1267/4076 |
58.90% 137/4524 |
-1.70% 2996/4813 |
| 2024 | 22.34% 381/3463 |
-3.13% 1470/2808 |
-0.06% 673/3014 |
15.53% 1691/3129 |
9.37% 332/3463 |
| 2023 | 5.71% 183/2656 |
25.58% 97/2280 |
-2.77% 660/2385 |
-10.35% 1987/2515 |
-3.43% 689/2655 |
| 2022 | -31.48% 1657/2207 |
-23.39% 1731/1919 |
0.73% 1530/2016 |
-16.08% 1400/2113 |
5.82% 435/2208 |
| 2021 | 9.68% 452/1822 |
-7.23% 1059/1255 |
16.03% 213/1330 |
-7.82% 1085/1466 |
10.53% 103/1822 |
| 2020 | 23.56% 651/1250 |
-1.20% 207/1028 |
24.04% 180/1067 |
-0.58% 1058/1164 |
1.41% 1032/1184 |
| 2019 | 48.96% 109/1092 |
38.51% 63/754 |
-11.53% 767/804 |
10.94% 41/850 |
9.56% 220/918 |
| 2018 | -34.13% 565/834 |
- - |
- - |
- - |
-13.81% 559/691 |
| 2017 | 5.22% 359/714 |
- - |
- - |
- - |
- - |
| 2016 | -25.22% 480/605 |
- - |
- - |
- - |
- - |
| 2015 | 65.46% 5/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 景顺中证科技传媒通信150ETF VS. 长安沪深300非周期A(740101) |